Protokolle zur Klassifikation, Überwachung und Therapie in der Kinderrheumatologie (PRO-KIND): Enthesitis-assoziierte Arthritis

• Literatur

• 1 Weller-Heinemann F, Ganser G, Sailer-Höck M. et al. Protokolle zur Klassifikation, Überwachung und Therapie in der Kinderrheumatologie (PROKIND): Polyartikuläre juvenile idiopathische Arthritis. Ergebnisse der Arbeitsgruppe Polyarthritis in der GKJR-Kommission PRO-KIND. arthritis + rheuma 2017; 37 (02) 136-141.
• 2 Hinze CH, Holzinger D, Lainka E. et al. Harmonisierung der Diagnostik und Therapie der systemischen juvenilen idiopathischen Arthritis in Deutschland. arthritis + rheuma 2017; 37 (04) 250-259.
• 3 Dueckers G, Guellac N, Arbogast M. et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142 (02) 176-193.
• 4 Niehues T. et al. S2k Leitlinie Juvenile Idiopathische Arthritis (JIA). Therapie. 2011 AEMFRegisternummer 027 – 020. http://www.awmf.org/uploads/tx_szleitlinien/027–020l_S2K_Juvenile_Idiopathische_Arthritis_2011–10_abgelaufen.pdf
• 5 Horneff G, Klein A, Ganser G. et al. Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017; 15 (01) 78.
• 6 Hinze CH, Holzinger D, Lainka E. et al. PROKIND SJIA project collaborators. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 2018; 16 (01) 7.
• 7 Ringold S, Nigrovic PA, Feldman BM. et al. The Childhood Arthritis & Rheumatology Research Alliance Consensus Treatment Plans: Towards Comparative Effectiveness in the Pediatric Rheumatic Diseases. Arthritis Rheumatol. 2018 Jan 15.
• 8 Kimura Y, Grevich S, Beukelman T. et al. CARRA Registry Investigators. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J 2017; 15 (01) 23.
• 9 Ringold S, Weiss PF, Colbert RA. et al. Juvenile Idiopathic Arthritis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014; 66 (07) 1063-1072.
• 10 DeWitt EM, Kimura Y, Beukelman T. et al. Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64 (07) 1001-1010.
• 11 Weiss PF, Xiao R, Brandon TG. et al. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. J Rheumatol 2018; 45 (01) 107-114.
• 12 Petty RE, Southwood TR. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31 (02) 390-392.
• 13 Dougados M, van der Linden S, Juhlin R. et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-1227.
• 14 Burgos-Vargas R. The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol Online J 2012; 10 (01) 14.
• 15 Sieper J, van der Heijde D, Landewe R. et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis 2009; 68: 784-788.
• 16 Consolaro A, Giancane G, Schiappapietra B. et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2016; 14 (01) 23.
• 17 Consolaro A, Bracciolini G. et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012; 64 (07) 2366-2374.
• 18 Weiss PF, Colbert RA, Xiao R. et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken) 2014; 66 (12) 1775-1782.
• 19 Sieper J. et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess Spondyloarthritis. Ann Rheum Dis 2009; 68 (Suppl II): ii1-ii44.
• 20 Gmuca S, Xiao R, Brandon TG. et al. Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthritis Res Ther 2017; 19: 84.
• 21 Weiß A, Minden K, Listing J. et al. Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. RMD Open 2017; 03 (01) e000366.
• 22 Beukelman T, Patkar NM. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63 (04) 465-482.
• 23 Berntson L, Damgård M, Andersson-Gäre B. et al. Nordic Paediatric Rheumatology Study Group. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol 2008; 35 (10) 2055-2061.
• 24 Selvaag AM, Flatø B, Dale K. et al. Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3-year prospective study. J Rheumatol 2006; 33 (07) 1382-1391.
• 25 Flatø B, Hoffmann-Vold AM, Reiff A. et al. Longterm outcome and prognostic factors in enthesitisrelated arthritis: a case-control study. Arthritis Rheum 2006; 54 (11) 3573-3582.
• 26 Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol 2015; 34 (11) 1839-1846.
• 27 Niewerth M, Klotsche J, Liedmann I. et al. Disease characteristics and disease activity in enthesitis-related arthritis during the first year of rheumatology care – results from an inception cohort study. EULAR, Rome, Annals of the Rheumatic Diseases 2015; 74 (Suppl. 02) 1233.
• 28 Shoop-Worrall SJW, Verstappen SMM, Baildam E. et al. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann Rheum Dis 2017; 76 (08) 1381-1388.
• 29 Consolaro A, Negro G, Chiara MGallo. et al. Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score. Arthritis Care Res (Hoboken) 2014; 66: 1703-1709.
• 30 Horneff G, Becker I. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score. Rheumatology (Oxford) 2014; 53 (07) 1229-1234.
• 31 Swart JF, van Dijkhuizen EHP, Wulffraat NM, de Roock S. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Ann Rheum Dis. 2017 Nov 14.
• 32 Haibel H, Fendler C, Listing J. et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebocontrolled short-term trial. Ann Rheum Dis 2014; 73 (01) 243-246.
• 33 Fischer T, Biedermann T. et al. Sacroiliitis in children with spondyloarthropathy: therapeutic effect of CT-Guided intra-articular corticosteroid injection. Rofo 2003; 175 (06) 814-821.
• 34 Burgos-Vargas R, Vazquez-Mellado J. et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002; 61 (10) 941-942.
• 35 van Rossum MA, Fiselier TJ. et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41 (05) 808-816.
• 36 Horneff G, Burgos-Vargas R, Constantin T. et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and safety of openlabel etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2014; 73 (06) 1114-1122.
• 37 Constantin T, Foeldvari I, Vojinovic J. et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. J Rheumatol 2016; 43 (04) 816-824.
• 38 Horneff G, Foeldvari I, Minden K. et al. Efficacy and safety of etanercept in enthesitis-related arthritis juvenile idiopathic arthritis: Results from a phase 3 randomized double-blind study. Arthritis Rheumatol 2015; 67 (08) 2240-2249.
• 39 Burgos-Vargas R, Tse SM, Horneff G. et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res (Hoboken) 2015; 67 (11) 1503-1512.
• 40 Horneff G, Fitter S, Foeldvari I. et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012; 14 (05) R230
• 41 Ramanan AV, Dick AD, Jones AP. et al. SYCAMORE Study Group. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med 2017; 376 (17) 1637-1646.
• 42 Hyams JS, Griffiths A, Markowitz J. et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 2012; 143 (02) 365-74 e2.
• 43 Inman RD, Davis Jr JC, van der Heijde D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58 (11) 3402-3412.
• 44 Mannion ML, McAllister L. et al. Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis. J Clin Rheumatol 2016; 22 (05) 282-284.
• 45 Baeten D, Baraliakos X, Braun J. et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382 (9906): 1705-1713.
• 46 van der Heijde D, Deodhar A, Wei JC. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017; 76 (08) 1340-1347.